What we checked before giving you this answer
We reviewed peer-reviewed dermatology literature, clinical guidelines from the American Academy of Dermatology, melanoma survival data from the SEER cancer registry, published studies on the accuracy of consumer mole-scanning apps, and systematic reviews on the diagnostic performance of dermoscopy. We did not simply repeat official guidance — we looked at whether that guidance is backed by outcome data. It is. Where the evidence diverges from common folk wisdom (such as the usefulness of smartphone apps), we say so plainly.
-
ABCDE criteria validated against biopsy outcomes Multiple published studies confirm that the ABCDE framework identifies melanoma with sensitivity above 90% when applied by a clinician, making it the most evidence-supported screening tool available outside a clinic.
-
Melanoma stage-at-detection survival data reviewed SEER data consistently shows five-year survival above 98% for stage 1 melanoma and below 25% for stage 4 — the strongest possible argument for early action rather than watchful waiting.
- "Smartphone app accuracy literature assessed" A 2021 systematic review in the Journal of the American Academy of Dermatology found consumer mole-scanning apps miss melanoma in up to 30% of cases — confirming they should not substitute for a clinical examination.